NasdaqGS:INVAPharmaceuticals
Innoviva’s NUZOLVENCE Approval And Buyback Reframe Growth And Valuation Story
Innoviva (NasdaqGS:INVA) received FDA approval for NUZOLVENCE, a first in class treatment for uncomplicated urogenital gonorrhea.
The company announced a US$125 million share repurchase program alongside the approval.
These updates point to meaningful shifts in Innoviva's specialty therapeutics focus and capital allocation approach.
For you as an investor, NUZOLVENCE adds a new approved therapy to Innoviva's portfolio, aligning with its push in specialty therapeutics. Gonorrhea treatment is...